Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Excerpt from the Press Release:
MARLBOROUGH, Mass., Oct. 7, 2021 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new data with PH-894, Phio’s self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The data presented add to the growing body of evidence that BRD4 not only plays a role in tumor cells, but can also regulate T cell function and that PH-894 can reprogram T cells to provide enhanced immunotherapeutic activity.
“The data we presented today at the AACR-NCI-EORTC meeting demonstrates silencing BRD4 with our INTASYL compound PH-894 has a significant impact on T cell function and phenotype promoting T cell activation and immunosuppression in the tumor microenvironment,” said Simon Fricker, Phio’s Vice President of R&D. “Our new data shows how BRD4 can regulate immune cells activity and therefore BRD4 silencing with PH-894 could become an important approach to treat cancer.”
In this study conducted in collaboration with the Karolinska Institutet in Sweden, it was shown that PH-894 resulted in a strong, concentration dependent and durable silencing of BRD4 in T cells, which in an in vivo study translated to pronounced and dose associated inhibition of tumor growth. These data demonstrate that Phio’s PH-894 INTASYL compound can reprogram T cells to provide enhanced immunotherapeutic activity.
“We are very excited by these data, which suggest that PH-894’s potency is not solely a consequence of its direct effect on tumor cells, but also its ability to reprogram and activate T cells to further boost the anti-cancer effect. As such, we are working hard on IND-enabling studies to bring this promising compound to the clinic,” continued Dr. Fricker.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?